Gudesblatt, Mark published the artcileHealth-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews, COA of Formula: C6H8O4, the publication is Advances in Therapy (2022), 39(7), 3199-3213, database is CAplus and MEDLINE.
Abstract: Introduction: Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS). Clin. and real-world studies of DRF have demonstrated improved gastrointestinal (GI) tolerability and low (< 1%) GI-related treatment discontinuation vs. di-Me fumarate (DMF) and high rates of treatment adherence. Our aim was to conduct a concept elicitation study to identify treatment-related concepts most meaningful to patients and to evaluate how these concepts shape the patient perspective of DRF. Methods: In-depth qual. interviews were conducted with patients from Oct. to Dec. 2020. US adults who had been prescribed DRF through routine clin. care and had taken DRF for ≥ 3 wk in the past 6 mo were eligible to participate. Semi-structured interviews explored patient perceptions on treatment selection and impact. Results: Seventeen patients participated in the study. Mean (SD) age was 49.3 (12.0) years. Sixteen patients reported prior disease-modifying therapy, while 10 (58.8%) had prior DMF. DRF treatment duration ranged from ∼ 6 wk to 10 mo. Four key concepts emerged: (1) overall wellness and quality of life, (2) ease of administration, (3) minimal and manageable side effects, and (4) patient optimism due to MS treatments. Mode of administration (82.4%), no/mild side effects (70.6%), convenience over injectable/infusion medications (58.8%), and effectiveness (64.7%) were cited as pos. aspects of DRF treatment. Frequent dosing (52.9%) and food requirements (41.2%) were cited as neg. attributes; however, 94.1% had no dietary changes since starting treatment. Conclusion: The patient perspective is a key aspect when considering a disease-modifying therapy for MS, given the multitude of options currently available. Overall wellness, ease of administration, and minimal and manageable side effects were DRF-related concepts most meaningful to patients on therapy. Acknowledging these patient perceptions in shared decision-making may lead to greater patient adherence and optimal treatment outcomes.
Advances in Therapy published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C6H8O4, COA of Formula: C6H8O4.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics